

Univ.-Prof. Dr. med. Michael P. Manns

President

Hannover Medical School (MHH)
 Carl-Neuberg-Str. 1, 30625 Hannover
 Tel.: +49 511 532-6000/ 6001
 Fax: +49 511 532-6003
 E-Mail: praesident@mh-hannover.de
 Homepage: <http://www.mhh.de>



Curriculum vitae

- | | | | |
|-----------|---|------------|--|
| 1970-1976 | Medical School, University of Vienna, Austria, and Johannes-Gutenberg-University, Mainz, Germany | since 2002 | Founder and Chairman of Hep-Net, national network of competence on viral hepatitis |
| 1976 | Doctor of Medicine | 2003-2006 | Commission of the senate of the German Research Foundation „DFG“ for Sonderforschungsbereiche (SFBs) |
| 1977 | Licence as MD | 2004-2010 | Founder of DFG Clinical Research Group on Hepatocellular Carcinoma (KF0 119) |
| 1977-1981 | Resident and Fellow, Department of Internal Medicine, Klinikum Charlottenburg, Free University of Berlin, Germany | 2004-2013 | Advisory Board, University Hospital Magdeburg |
| 1981-1985 | Resident and Fellow, Department of Medicine I, University of Mainz, Germany | 2005-2009 | Chairman, Center of Internal Medicine, Medical School of Hannover |
| 1984 | Licence for Internal Medicine | 2005-2009 | Steering committee member of VIRGIL, EU network of excellence on viral resistance in flue and viral hepatitis |
| 1985 | Subspecialist for Gastroenterology and Hepatology | since 2006 | Founder and President, German Liver Foundation 2006 President, German Society of Gastroenterology (DGVS) |
| 1985-1991 | Staff Physician (Oberarzt), Department of Medicine I, University of Mainz; Germany | 2006-2018 | Member, Steering Committee of REBIRTH, DFG Cluster of Excellence on Regenerative Medicine |
| 1986 | Professor of Medicine and Gastroenterology, University of Mainz | 2007-2019 | Chairman, DFG Sonderforschungsbereich 738 "Optimizing conventional and innovative transplants" (collaborative project) |
| 1987-1988 | Research Associate – W.M. Keck Autoimmune Disease Centre, Scripps Clinic and Research Foundation, Dept. of Basic and Clinical Research, La Jolla, CA, USA | 2008-2018 | Member, Steering Committee of BMBF-IFB, integrated center for research and treatment in transplantation medicine |
| 1991-2020 | Chairman, Department of Gastroenterology, Hepatology and Endocrinology, Center of Internal Medicine, Medical School of Hannover (MHH) | since 2009 | Member, Advisory Board, University Hospital Mainz, Germany |
| 1997-1999 | Medical Director, MHH | 2010-2014 | Vice Chairman, Transregio - SFB 77, "Liver Cancer" |
| 1997-2003 | Chairman, Sonderforschungsbereich 265 (collaborative project) of DFG "Pathophysiology and Immune Reactions after Organ Transplantation" | since 2010 | Member, commission for structures in academic medicine (MSK), Baden- Württemberg, Stuttgart |
| 1998-2020 | Member, Scientific Advisory Board, Robert Koch Institute, Berlin | 2011-2018 | Coordinator, Translational Thematic Unit Hepatitis, Centre for Infection Research (DZIF) |
| 1998-2013 | Member Advisory Board, University Hospital Erlangen, Germany | 2011-2019 | Member, selection committee, Alexander von Humboldt Foundation, Bonn, Germany |
| 1999-2001 | Member, Senate of MHH | | |
| 2009-2011 | Member, Senate of MHH | | |
| 2013-2018 | Member, Senate of MHH | | |

- since 2011 Member, External Scientific Council, Vall d'Hebron Institute of Research (VHIR), Universitat Autònoma de Barcelona, Spain
- 2011-2015 Member, European BioMedAlliance, Brussels
- 2015-2020 Board Member, Boehringer Ingelheim Foundation since 2015 Member, Scientific Panel for Health (SPH), European Commission, Brussels
- 2015-2018 Clinical Director, Helmholtz Centre for Infection Research (HZI), Braunschweig
- 2015-2018 Founding Director, Centre for Individualised Infection Medicine (CIIM), Hannover
- 2016-2020 Member, Board of Trustees of the University of Lübeck
- since 2017 Vice Chairman, Transregio-SFB 209 „Liver Cancer – New mechanistic and therapeutic concepts in a solid tumor model“
- since 2019 President, Hannover Medical School (MHH), Germany
- since 2006 Honorary Member, Hungarian Society of Gastroenterology
- 2006 Corriere della Sera, Milano: MHH Department of Gastroenterology, Hepatology and Endocrinology is leading centre for liver research in Europe
- 2007 EASL Recognition Award, Barcelona, Spain
- 2008 Sheila Sherlock State-of-the-Art Lecture, British Society of Gastroenterology, Birmingham, UK
- 2008 Most cited European author in Gastroenterology and Hepatology (1996 – 2006) (www.lab-times.org)
- 2009 Hippokrates Award, Hellenic Society of Internal Medicine, Athens
- 2010 Resnick Lecturer and Visiting Professor, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA
- 2011 Ulrika Broome Lecture, Swedish Society of Gastroenterology, Umea, Sweden
- 2011 Sherbaniuk-Wensel Lectureship, University of Alberta, Edmonton, Canada

Activities in the scientific community, honors, awards

- 1985 Boehringer Ingelheim Award, University of Mainz, Germany
- 1990 NATO Collaboration Research Award, Brussels, Belgium
- 1990 Clinical Research Award, GSK Foundation, Göttingen
- 1991 Clemens van Pirquet Award, University of California Davis, USA
- 1991 Ralph Wright Memorial Lecture, British Association for the Study of the Liver, London, UK
- 1993 Sheila Sherlock State of the Art Lecture, Int. Association for the Study of the Liver, Cancun, Mexico
- 1995 International Hans Popper Award Basel, Switzerland
- 1997 Sir Michael Perrin Lecture, Royal College of Physicians, London, UK
- 2000 Leon Schiff State-of-the-Art Lecture, American Association for the Study of the Liver, Dallas, USA
- 2002 Dr. Robert-Pfleger-Award, Bamberg, Germany (German Academy of Science)
- since 2002 Member, Leopoldina, National Academy of Science, Halle, Germany
- 2003 Max-Siurala-Award, Finish Society of Gastroenterology, Turku, Finland
- since 2004 Member, Academy of Science, Göttingen
- since 2005 Honorary Member, Argentinian Association for the Study of the Liver
- 2006 President, German Society of Gastroenterology (DGVS)
- 2012 Corresponding member, Academy of Science, and Literature Mainz, Germany
- 2012 Int. Hans Popper Lecturer, Medical University of Vienna, Vienna, Austria
- 2013 President, German Ass. for the Study of the Liver (GASL)
- 2013-2014 President, German Society of Internal Medicine (DGIM)
- since 2014 Thomson Reuters Highly Cited Researcher, ranking among the top 1 % most cited researchers in the field (clinical medicine)
- 2015 Sheila Sherlock Lecturer, Toronto University, Toronto, Canada
- 2015 Tzu-Leung Ho Lecturer, International Digestive Disease Forum, Hong Kong
- 2015 Roy Calne-Roger Williams Lecture of the British Association for the Study of the Liver (BASL), London, UK
- since 2015 Associate Editor, Clinical Gastroenterology and Hepatology
- 2016-2017 President, United European Gastroenterology (UEG)
- 2016 Ring of Honor, City of Garbsen, Garbsen, Germany
- 2019 Honorary Member, Austrian Society of Gastroenterology and Hepatology, (ÖGGH)

Research fields

- inflammatory liver diseases, viral and autoimmune
- clinical trials for the treatment of liver diseases, in particular viral hepatitis, autoimmune liver diseases, liver transplantation
- transplantation medicine
- gastrointestinal oncology, in particular hepatocellular carcinoma
- regenerative medicine
- clinical pharmacology

Selected publications

Manns MP, Meyer zum Bueschenfelde KH. A mitochondrial antigen-antibody system in cholestatic liver disease detected by radioimmunoassay. *Hepatology* 2: 1-7 (1982).

Manns MP, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Bueschenfelde KH. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. *The Lancet* 1: 292-294 (1987).

Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. The major antigen of liver-kidneymicrosomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450 db1. *J Clin Invest* 83: 1066-1079 (1989).

Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P4502D6, a cytochrome P450 monooxygenase. *J Clin Invest* 88(4): 1370-1378 (1991).

Michel G, Ritter A, Gerken G, Meyer zum Bueschenfelde KH, Decker R, **Manns MP**. Anti- GOR and hepatitis C virus in autoimmune liver diseases. *The Lancet* 339: 267-9 (1992).

Philipp T, Durazzo M, Trautwein C, Alex B, Straub P, Lamb G, Johnson EF, Tukey RH, **Manns MP**. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. *The Lancet* 344: 578-581 (1994).

Desmet V, Gerber MA, Hoofnagle JH, **Manns MP**, Scheuer P. Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology* 19: 1513-20 (1994).

Takaki, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, Miller JL, **Manns MP**, Rehermann B. Cellular immune responses persist, humoral responses decline two decades after recovery from a single source outbreak of hepatitis C. *Nat Med* 6: 578-582 (2000).

Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, **Manns MP**. German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon alfa-2b. *N Engl J Med*. 15;345: 1452-1457 (2001).

Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *The Lancet*. 358: 958-65 (2001).
(*meistzitierte Publikation in Gastroenterologie und Hepatologie*)

Tillmann HL, Heiken H, Knapik-Botor A, Heringlake S, Ockenga J, Wilber JC, Georgen B, Detmer J, McMorro M, Stoll M, Schmidt RE, **Manns MP**. Infection with GB virus C and reduced mortality among HIV-infected patients. *N Engl J Med* 345: 715-724 (2001).

Zender L, Hütker S, Liedke C, Tillmann HL, Zender S, Mundt B, Waltemathe M, Gösling T, Flemming P, Malek NP, Trautwein C, **Manns MP**, Kühnel F, Kubicka S. Caspase 8 siRNA prevents acute liver failure in mice. *Proc Natl Acad Sci USA* 100: 7797-802 (2003).

Kossatz U, Vervoorts J, Nickeleit I, Sundberg HA, Arthur JS, **Manns MP**, Malek NP. C-terminal phosphorylation controls the stability and function of p27kip1. *EMBO J* 25: 5159-5170 (2006).

Timmerbeul I, Garrett-Engele CM, Kossatz U, Chen X, Firpo E, Grünwald V, Kamino K, Wilkens L, Lehmann U, Buer J, Geffers R, Kubicka S, **Manns MP**, Porter PL, Roberts JM, Malek NP. Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. *Proc Natl Acad Sci USA* 103: 14009-14014 (2006).

Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment—finding the right path. *Nat Rev Drug Discov* 6(12): 991-1000 (2007).

Holdener M, Hintermann E, Bayer M, Rhode A, Rodrigo E, Hintereder G, Johnson EF, Gonzalez FJ, Pfeilschifter J, **Manns MP**, Herrath MG, Christen U. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. *J Exp Med* 205: 1409-22 (2008).

Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, **Manns M**, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. *N Engl J Med* 359: 2442-55 (2008).

Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. AASLD Practice Guidelines: Diagnosis and Management of Autoimmune Hepatitis. *Hepatology* 51: 2193-2213 (2010).

McHutchison JG, **Manns MP**, Muir AJ, Terrault NA, Jacobson IM, Afdahl NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, DiBisceglie AM and the PROVE 3 Study Team. Telaprevir combined with Peginterferon and ribavirin in hepatitis C patients who have not had a sustained virologic response to initial interferonbased therapy. *N Engl J Med* 362: 1292 – 303 (2010) .

Manns MP, Woynarkowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, Bahr MJ, Gunther R, Hultcrantz RW, Spengler U, Lohse AW, Szalay F, Farkkila M, Proels M, Strassburg CP. Azathioprine with budesonide induces remission more effectively than with prednisone in patients with autoimmune hepatitis. *Gastroenterology* 139: 1198-1206 (2010).

Lankisch TO, Metzger J, Negm AA, Vosskuhl K, Schiffer E, Siwy J, Weismüller TJ, Schneider AS, Thedieck K, Baumeister R, Zürlig P, Weissinger EM, **Manns MP**, Mischak H, Wedemeyer J. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. *Hepatology*; 53:875-84 (2011)

Wedemeyer H, Yurdaydin C, Dalekos G, Ehrhardt A, Cakaloglu Y, Degertekin K, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Bock CT, Dienes H, **Manns MP**. Peginterferon plus Adefovir versus either drug alone for hepatitis delta. *New Engl J Med* 364: 322 – 331 (2011).

Poordad F, McCone J Jr, Bacon BR, Bruno S, **Manns MP**, Sulkowski MS, Jacobson IM, Reddy KR, Goodman Z, Boprai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. *New Engl J Med*, 364: 1195-206 (2011).

Kang TW, Yevsa T, Woller N, Hoenecke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, Iken M, Vucur M, Weiss S, Heikenwalder M, Khan S, Gil J, Bruder D, **Manns M**, Schirmacher P, Tacke F, Ott M, Luedde T, Longerich T, Kubicka S, Zender L. Senescence surveillance of premalignant hepatocytes limits liver cancer development. *Nature*, 479: 547–551 (2011).

Zender S, Nicleleit I, Wuestefeld T, Sörensen I, Dauch D, Bozko P, El-Khatib M, Geffers R, Bektas H, **Manns MP**, Gossler A, Wilkens L, Plentz R, Zender L, Malek NP. A critical role for notch signaling in the formation of cholangiocellular carcinomas. *Cancer Cell* 23: 784-95 (2013)

Wuestefeld T, Pesic M, Rudalska R, Dauch D, Longerich T, Kang TW, Yevsa T, Heinzmann F, Hoenicke L, Hohmeyer A, Potapova A, Rittelmeier I, Jarek M, Geffers R, Scharfe M, Klawonn F, Schirmacher P, Malek NP, Ott M, Nordheim A, Vogel A, **Manns MP**, Zender L. A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. *Cell* 153: 389-401 (2013).

Woynarowski M, Nemeth A, Baruch Y, Koletzko S, Melter M, Rodeck B, Strassburg C, Pröls M, Wozniak M, **Manns MP**, European Autoimmune Hepatitis-Budesonide Study Group. Budesonide versus Prednisone with Azathioprine for the Treatment of Autoimmune Hepatitis in Children and Adolescents. *The Journal of Pediatrics* 163: 1347-53 (2013).

Deterding K, Grüner N, Buggisch P, Wiegand J, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Malek N, Großhennig A, Koch A, Diepolder H, Lüth S, Feyerabend S, Jung MC, Rogalska-Taranta M, Schlapphoff V, Cornberg M, **Manns MP**, Wedemeyer H; Hep-Net Acute HCV-III Study Group, Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled noninferiority trial. *Lancet Infect Dis*. 13: 497-506 (2013).

Manns MP, von Hahn T. Novel therapies for hepatitis C - one pill fits all? *Nat Rev Drug Discovery* 12: 595-610 (2013).

Manns M, Marcellin P, Poordad F, Affonso de Araujo S A, Buti M, Horsmans Y, Janczewska W, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, de la Rosa G, Kalmeijer R, Sinha R, Beumont-Maiviel M. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naïve patients with chronic hepatitis c virus genotype 1 infection (QUEST-2): a randomized, double-blind, placebo-controlled phase 3 trial. *The Lancet* 384: 414-426 (2014).

Manns M, Pol S, Jacobsen IM, Marcellin P, Gordon SC, Peng C-H, Chang T-T, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu C-J, Sievert W, Bronowicki J-P, Thabut D, Lee Y-J, Kao J-H, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S, on behalf of the HALLMARK-DUAL Study Team: All oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. *The Lancet* 384: 1597-1605 (2014).

Charlton M, Gane E, **Manns MP**, Brown RS Jr, Curry MP, Kwo PY, Fontana RJ, Gilroy R, Teperman L, Muir AJ, McHutchison JG, Symonds WT, Brainard D, Kirby B, Dvory-Sobol H, Denning J, Arterburn S, Samuel D, Fornis X, Terrault NA. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. *Gastroenterology* 148: 108-17 (2015).

Negro F, Forton D, Craxi A, Sulkowski MS, Feld JJ, **Manns MP**. Extrahepatic Morbidity and mortality of chronic hepatitis C. *Gastroenterology* 149: 1345-1360 (2015).

Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, Müllhaupt B, Agarwal K, Angus P, Yoshida EM, Colombo M, Rizzetto M, Dvory-Sobol H, Denning J, Arterburn S, Pang PS, Brainard D, McHutchison JG, Dufour F, Van Vlierberghe H, van Hoek B, Fornis X for the SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. *Lancet Infect Dis* 16: 685-97 (2016)

Yang D, Yuan Q, Balakrishnan A, Bantel H, Klusmann JH, **Manns MP**, Ott M, Cantz T, Sharma AD. MicroRNA-125b-5p mimic inhibits acute liver failure. *Nat Commun* 7:11916 (2016).

Manns MP, Buti M, Gane EJ, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Nature Reviews Disease Primars - Hepatitis C virus infection. *Nat Rev Dis Primers*. 3, 17006 (2017).

Deterding K, Spinner CD, Schott E, Welzel TM, Gerken G, Klinker H, Spengler U, Wiegand J, Schulze Zur Wiesch J, Pathil A, Cornberg M, Umgelter A, Zöllner C, Zeuzem S, Papkalla A, Weber K, Hardtke S, von der Leyen H, Koch A, von Witzendorff D, **Manns MP**, Wedemeyer H; HepNet Acute HCV IV Study Group, Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 mono-infection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. *Lancet Infect Dis*; 17:215-22 (2017).

Bourlière M, Bourlière M1, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, **Manns MP**, Kowdley KV, Zeuzem S; POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. *N Engl J Med* 2017 376(22):2134-2146 (2017)

Strunz B, Hengst J, Deterding K, **Manns MP**, Cornberg M, Ljunggren HG, Wedemeyer H, Björkström NK; Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity. *Nat Commun*. 2018 9(1):2275 (2018)

Manns MP, Burra P, Sargent J, Horton R, Karlsen TH; The Lancet-EASL Commission on liver diseases in Europe: overcoming unmet needs, stigma, and inequities. *Lancet*. 2018 392(10148):621-622 (2018)

Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, **Manns MP**; HIDIT-II study team; Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. *Lancet Infect Dis* 2019 19(3):275-286 (2019)

Niemann J, Woller N, Brooks J, Fleischmann- Mundt B, Martin NT, Kloos A, Knocke S, Ernst AM, **Manns MP**, Kubicka S, Wirth TC, Gerardy- Schahn R, Kühnel F; Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy. *Nat Commun*. 2019 10 (1):3236 (2019)

Mack CL, Adams D, Assis DN, Kerkar N, **Manns MP**, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ; Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the study of liver diseases. *Hepatology* 2019. Epub ahead of print (2019)

Goepfert B, Folseraas T, Roessler S, Kloor M, Volckmar AL, Endris V, Buchhalter I, Stenzinger A, Grzyb K, Grimsrud MM, Gornicka B, von Seth E, Reynolds GM, Franke A, Gotthardt DN, Mehrabi A, Cheung A, Verheij J, Arola J, Mäkisalo H, Eide TJ, Weidemann S, Cheville JC, Mazza G, Hirschfield GM, Ponsioen CY, Bergquist A, Milkiewicz P, Lazaridis KN, Schramm C, **Manns MP**, Färkkilä M, Vogel A; International PSC study group, Boberg KM, Schirmacher P, Karlsen TH; Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals novel therapeutic opportunities. *Hepatology* 2020. Epub ahead of print (2020)

*More than 1000 publications, Hirsch Index 160
(Google Scholar, 16 January 2020)*

